Prognostic prediction of glioblastoma by quantitative assessment of the methylation status of the entire MGMT promoter region.

ABSTRACT:

Background

O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation is reported to be a prognostic and predictive factor of alkylating chemotherapy for glioblastoma patients. Methylation specific PCR (MSP) has been most commonly used when the methylation status of MGMT is assessed. However, technical obstacles have hampered the implementation of MSP-based diagnostic tests. We quantitatively analyzed the methylation status of the entire MGMT promoter region and applied this information for prognostic prediction using sequencing technology.

Methods

Between 1998 and 2012, the genomic DNA of 85 tumor samples from newly diagnosed glioblastoma patients was subjected to bisulfite treatment and subdivided into a training set, consisting of fifty-three samples, and a test s

SUBMITTER: Kanemoto M 

PROVIDER: S-EPMC4161852 | biostudies-literature | 2014 Aug

REPOSITORIES: biostudies-literature